A phase-1 trial of linsitinib (OSI-906) in combination with bortezomib and dexamethasone for the treatment of relapsed/refractory multiple myeloma

TY - JOUR

T1 - A phase-1 trial of linsitinib (OSI-906) in combination with bortezomib and dexamethasone for the treatment of relapsed/refractory multiple myeloma

AU - White, Darrell

N1 - Publisher Copyright: © 2021 Informa UK Limited, trading as Taylor & Francis Group.

PY - 2021

Y1 - 2021

KW - IGF-1R

KW - Multiple myeloma

KW - linsitinib

KW - phase 1

UR - http://www.scopus.com/inward/record.url?scp=85100166022&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85100166022&partnerID=8YFLogxK

U2 - 10.1080/10428194.2021.1876864

DO - 10.1080/10428194.2021.1876864

M3 - Article

C2 - 33509009

AN - SCOPUS:85100166022

SN - 1042-8194

VL - 62

SP - 1721

EP - 1729

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

IS - 7

ER -